Recent Updates — TIVC
Valion Bio received unsolicited acquisition inquiries from independent third parties regarding its wholly owned contract development and manufacturing subsidiary, Velocity Bioworks. The company has entered preliminary discussions with interested parties while evaluating a range of strategic options for the unit, including a potential sale. Valion has retained an investment banking firm to advise the Board on these matters. Discussions remain preliminary, and no definitive agreement or commitment to sell has been reached. The company aims to maximize asset value while retaining production rights for its lead drug candidate, Entolimod. Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways.
Valion Bio appointed Dean Zikria as interim chief executive officer. Zikria outlined a strategic agenda prioritizing the advancement of lead asset Entolimod for Acute Radiation Syndrome, commercial expansion of CDMO subsidiary Velocity Bioworks, and evaluation of strategic transactions such as partnerships or sales to unlock value. The company has not committed to any specific transaction regarding Velocity. Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways.
On October 15, 2026, Valion Bio announced that its wholly owned CDMO subsidiary, Velocity Bioworks, completed an initial feasibility evaluation of LarmorBio’s BioScan-NMR™ platform. The evaluation demonstrated a strong correlation between NMR measurements and optical density at 600 nm (OD600), supporting the potential for continuous, real-time, non-invasive monitoring of microbial growth during fermentation processes. This milestone validates early-stage proof-of-concept data aimed at reducing reliance on invasive sampling and lowering manufacturing costs. Valion Bio is a biopharmaceutical company developing biologics that activate innate immune pathways, with lead candidates Entolimod and Entolasta targeting acute radiation syndrome and oncology supportive care.
Valion Bio, Inc. entered into a letter agreement with 3i, LP to issue 50 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 1,539 common shares at $2.5520 per share for an aggregate price of $50,000. The transaction was conducted under a private placement exemption. Valion Bio operates in the biotechnology sector.
Valion Bio, Inc. announced that Thomas H. Jensen has been appointed as the company's new Board Chair, effective September 2026. Jensen brings over 20 years of biotechnology experience and currently serves as CEO and Director at Allarity Therapeutics, where he led a strategic refocusing around its lead asset. He will work with Interim CEO Dean Zikria to align Valion's priorities on advancing Entolimod, an investigational TLR5 agonist for acute radiation syndrome that has received FDA Fast Track and Orphan Drug designations. The company operates as a clinical-stage biopharmaceutical firm developing biologics targeting innate immune pathways.